Akesis Pharmaceuticals Engages Quintiles Transnational Corp and dgd Research for Clinical Services

SAN DIEGO--(BUSINESS WIRE)--Akesis Pharmaceuticals, Inc. (OTCBB:AKES), an emerging diabetes drug-development company, today announced it has engaged Quintiles Transnational Corp and dgd Research to provide analytical and clinical services related to the Company’s lead product candidate, AKP-020, otherwise known as bis(ethylmaltolato)oxovanadium (IV), or BEOV. Pending FDA review and approval, Quintiles will be responsible for overall project supervision and data management for upcoming trials, while dgd Research will be conducting the planned Phase Ib human clinical trials in its San Antonio facility.